New combo aims to extend cancer remission after liver surgery

NCT ID NCT01312857

Completed Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the targeted drug panitumumab to standard chemotherapy (given through the liver artery and a vein) could help keep colorectal cancer from returning after liver metastases were surgically removed. It involved 75 adults with a specific gene type (wild-type RAS) and no cancer outside the liver. The goal was to see if the combination could lengthen the time patients stayed cancer-free.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA METASTATIC TO THE LIVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Rockville Centre

Rockville Centre, New York, 11570, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.